TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF EUROPE BLOOD SCREENING MARKET 30
1.4 CURRENCY AND PRICING 31
1.5 LIMITATION 32
1.6 MARKETS COVERED 32
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHIC SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 RESEARCH METHODOLOGY 39
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.7 DBMR MARKET POSITION GRID 43
2.8 THE CATEGORY VS TIME GRID 44
2.9 THE CATEGORY VS TIME GRID 45
2.10 DBMR MARKET CHALLENGE MATRIX 46
2.11 SECONDARY SOURCES 47
2.12 ASSUMPTIONS 47
3 MARKET OVERVIEW 48
3.1 DRIVERS 50
3.1.1 RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS 50
3.1.2 RISING PREVALENCE IN NUMBER OF DISEASES 50
3.1.3 RISING NUMBER OF INITIATIVES BY VARIOUS GOVERNMENTS AND GOVERNMENT ASSOCIATIONS 51
3.2 RESTRAINTS 52
3.2.1 LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES 52
3.2.2 HIGH COST OF TECHNOLOGY AND INSTRUMENTS 52
3.2.3 EMERGING ALTERNATIVE TECHNOLOGIES 53
3.3 OPPORTUNITIES 54
3.3.1 INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING 54
3.4 CHALLENGES 55
3.4.1 REDUCTION IN PRICE FOR TECHNOLOGY AND INSTRUMENT 55
4 EXECUTIVE SUMMARY 56
5 PREMIUM INSIGHTS 59
6 EUROPE BLOOD SCREENING MARKET, BY PRODUCTS & SERVICES 61
6.1 OVERVIEW 62
6.2 REAGENTS & KITS 64
6.2.1 ELISA REAGENTS & KITS 66
6.2.1.1 IMMUNOSORBENTS 67
6.2.1.2 CONJUGATES 67
6.2.1.3 SUBSTRATES 67
6.2.1.4 CONTROLS 67
6.2.1.5 SAMPLE DILUENTS AND WASH SOLUTIONS 67
6.2.2 NAT REAGENTS & KITS 67
6.2.2.1 PROBES AND PRIMERS 68
6.2.2.2 ENZYMES AND POLYMERASES 68
6.2.2.3 LABELING AND DETECTION REAGENTS 68
6.2.2.4 STANDARDS AND CONTROLS 68
6.2.2.5 BUFFERS, NUCLEOTIDES AND SOLUTIONS 68
6.3 INSTRUMENTS 69
6.3.1.1 INSTRUMENTS, PRODUCT TYPE 70
6.3.1.1.1 SEMI AUTOMATED 70
6.3.1.1.2 AUTOMATED 70
6.3.1.2 INSTRUMENTS, PURCHASE TYPE 70
6.3.1.2.1 OUTRIGHT PURCHASE 70
6.3.1.2.2 RENTAL 70
6.4 SOFTWARE & SERVICES 71
7 EUROPE BLOOD SCREENING MARKET, BY TECHNOLOGY 72
7.1 OVERVIEW 73
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 75
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY PLATFORM 77
7.2.1.1 COLORIMETRIC IMMUNOASSAY (CI) 77
7.2.1.2 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) 77
7.2.1.3 FLUORESCENCE IMMUNOASSAY (FIA) 77
7.2.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY GENERATIONS 77
7.2.2.1 FIRST-GENERATION ELISA 77
7.2.2.2 SECOND-GENERATION ELISA 77
7.2.2.3 THIRD-GENERATION ELISA 77
7.2.2.4 FOURTH-GENERATION ELISA 77
7.3 RAPID TESTS 78
7.4 NEXT-GENERATION SEQUENCING (NGS) 79
7.5 NUCLEIC ACID TEST 80
7.5.1 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 81
7.5.2 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 81
7.6 WESTERN BLOT ASSAY 82
7.7 OTHERS 83
8 EUROPE BLOOD SCREENING MARKET, BY DISEASE TYPE 84
8.1 OVERVIEW 85
8.2 ONCOLOGY 87
8.3 DIABETES MELLITUS 88
8.4 COLD & FLU 89
8.5 CHOLESTEROL 90
8.6 INFECTIOUS DISEASES 91
8.7 RESPIRATORY DISEASES 92
8.8 HIV/AIDS 93
8.9 OTHERS 94
9 EUROPE BLOOD SCREENING MARKET, BY END USER 95
9.1 OVERVIEW 96
9.2 DIAGNOSTIC CENTERS 98
9.3 BLOOD BANK 99
9.4 HOSPITALS 100
9.5 CLINICS 101
9.6 AMBULATORY SURGICAL CENTERS 102
10 EUROPE BLOOD SCREENING MARKET, BY GEOGRAPHY 103
10.1 EUROPE 103
10.1.1 GERMANY 114
10.1.2 U.K. 121
10.1.3 FRANCE 128
10.1.4 ITALY 135
10.1.5 SPAIN 142
10.1.6 SWITZERLAND 149
10.1.7 NETHERLANDS 156
10.1.8 BELGIUM 163
10.1.9 RUSSIA 170
10.1.10 TURKEY 177
10.1.11 REST OF EUROPE 184
11 EUROPE BLOOD SCREENING MARKET, COMPANY LANDSCAPE 185
11.1 COMPANY SHARE ANALYSIS; EUROPE 185
12 COMPANY PROFILES 186
12.1 F. HOFFMANN-LA ROCHE LTD 186
12.1.1 COMPANY OVERVIEW 186
12.1.2 REVENUEANALYSIS 186
12.1.3 COMPANY SHARE ANALYSIS 187
12.1.4 PRODUCT PORTFOLIO 187
12.1.5 RECENT DEVELOPMENT 188
12.2 ABBOTT 189
12.2.1 COMPANY OVERVIEW 189
12.2.2 REVENUE ANALYSIS 189
12.2.3 COMPANY SHAREV ANALYSIS 190
12.2.4 PRODUCT PORTFOLIO 190
12.2.5 RECENT DEVELOPMENT 191
12.3 THERMO FISHER SCIENTIFIC INC. 192
12.3.1 COMPANY OVERVIEW 192
12.3.2 REVENUE ANALYSIS 192
12.3.3 COMPANY SHAREV ANALYSIS 193
12.3.4 PRODUCT PORTFOLIO 193
12.3.5 RECENT DEVELOPMENTS 194
12.4 SIEMENS AG 195
12.4.1 COMPANY OVERVIEW 195
12.4.2 REVENUE ANALYSIS 195
12.4.3 COMPANY SHAREV ANALYSIS 196
12.4.4 PRODUCT PORTFOLIO 196
12.4.5 RECENT DEVELOPMENTS 198
12.5 BIO-RAD LABORATORIES, INC. 199
12.5.1 1.3.1COMPANY OVERVIEW 199
12.5.2 REVENUE ANALYSIS 199
12.5.3 COMPANY SHAREV ANALYSIS 200
12.5.4 PRODUCT PORTFOLIO 200
12.5.5 RECENT DEVELOPMENTS 202
12.6 BD 203
12.6.1 COMPANY OVERVIEW 203
12.6.2 REVENUE ANALYSIS 203
12.6.3 PRODUCT PORTFOLIO 204
12.6.4 RECENT DEVELOPMENTS 204
12.7 BECKMAN COULTER, INC. 205
12.7.1 COMPANY OVERVIEW 205
12.7.2 GEOGRAPHICPRESENCE 205
12.7.3 PODUCT PORTFOLIO 206
12.7.4 RECENET DEVELOPEMENTS 207
12.8 BIOM?RIEUX SA 208
12.8.1 COMPANY OVERVIEW 208
12.8.2 REVENUE ANALYSIS 208
12.8.3 PRODUCT PORTFOLIO 209
12.8.4 RECENT DEVELOPMENT 210
12.9 CEPHEID (A SUBSIDIARY OF DANAHER CORPORATION) 211
12.9.1 COMPANY OVERVIEW 211
12.9.2 GEOGRAPHIC PRESENCE 211
12.9.3 PRODUCT PORTFOLIO 212
12.9.4 RECENT DEVELOPMENT 213
12.10 ENZO BIOCHEM INC. 214
12.10.1 COMPANY OVERVIEW 214
12.10.2 REVENUE ANALYSIS 214
12.10.3 PRODUCT PORTFOLIO 215
12.10.4 RECENT DEVELOPMENTS 216
12.11 GRIFOLS INTERNATIONAL, S.A. 217
12.11.1 COMPANY OVERVIEW 217
12.11.2 REVENUE ANALYSIS 217
12.11.3 PRODUCT PORTFOLIO 218
12.11.4 RECENT DEVELOPMENTS 219
12.12 HOLOGIC INC. 220
12.12.1 COMPANY OVERVIEW 220
12.12.2 REVENUE ANALYSIS 220
12.12.3 PRODUCT PORTFOLIO 221
12.12.4 RECENT DEVELOPMENTS 221
12.13 IMMUCOR, INC. 222
12.13.1 COMPANY OVERVIEW 222
12.13.2 GEOGRAPHIC PRESENCE; 222
12.13.3 PRODUCT PORTFOLIO 223
12.13.4 RECENT DEVELOPMENTS 224
12.14 MERIDIAN BIOSCIENCE, INC. 225
12.14.1 COMPANY OVERVIEW 225
12.14.2 REVENUE ANALYSIS 225
12.14.3 PRODUCT PORTFOLIO 226
12.14.4 RECENT DEVELOPMENTS 227
12.15 ORTHO CLINICAL DIAGNOSTICS 228
12.15.1 COMPANY OVERVIEW 228
12.15.2 GEOGRAPHIC PRESENCE 228
12.15.3 PRODUCT PORTFOLIO 229
12.15.4 RECENT DEVELOPMENTS 230
13 RELATED REPORTS 231
?